Piccioni, Federica

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell

Gene expression and cancer classificationBioinformatics and Genomic Networks

Cited by 3,515

Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities

Sanson, K. R., Hanna, R. E., Hegde, M., Donovan, K. F., Strand, C., Sullender, M. E., Vaimberg, E. W., Goodale, A., Root, D. E., Piccioni, F., et al. (2018) · Nature Communications

CRISPR and Genetic EngineeringChromatin Remodeling and Cancer

Cited by 1,043

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell

Hippo pathway signaling and YAP/TAZProtein Kinase Regulation and GTPase Signaling

Cited by 744

Mutational processes shape the landscape of TP53 mutations in human cancer

Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics

Cancer-related Molecular PathwaysCancer Genomics and Diagnostics

Cited by 556

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 452

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 441

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell

Cell death mechanisms and regulationChronic Lymphocytic Leukemia Research

Cited by 361

Natural variation in gene expression and viral susceptibility revealed by neural progenitor cell villages

Wells, M. F., Nemesh, J., Ghosh, S., Mitchell, J. M., Salick, M. R., Mello, C. J., Meyer, D., Pietilainen, O., Piccioni, F., Guss, E. J., et al. (2023) · Cell Stem Cell

Single-cell and spatial transcriptomicsGenetic Associations and Epidemiology

Cited by 116

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers

Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 90

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase

Garvie, C. W., Wu, X., Papanastasiou, M., Lee, S., Fuller, J., Schnitzler, G. R., Horner, S. W., Baker, A., Zhang, T., Mullahoo, J. P., et al. (2021) · Nature Communications

Phosphodiesterase function and regulationProtein Tyrosine Phosphatases

Cited by 85

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer

Stover, E. H., Baco, M. B., Cohen, O., Li, Y. Y., Christie, E. L., Bagul, M., Goodale, A., Lee, Y., Pantel, S., Rees, M. G., et al. (2019) · Molecular Cancer Research

Cell death mechanisms and regulationOvarian cancer diagnosis and treatment

Cited by 49